Founded in 1999, Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. Fluidigm successfully completed its initial public offering and then began trading on NASDAQ under the symbol “FLDM” on February 10, 2011.